$3.20
-0.05-1.54%
At Close: -
$3.31
0.113.44%
After Hours: 9:26 AM EDT
15 minutes delayed
Aldeyra Therapeutics
ALDXNASDAQ
Aldeyra Therapeutics (NASDAQ:ALDX) Stock, Analyst Ratings, Price Targets, Predictions
Aldeyra Therapeutics Inc has a consensus price target of $9.67, established from looking at the 20 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Oppenheimer, and Oppenheimer on May 6, 2024, May 6, 2024, and April 3, 2024. With an average price target of $10 between HC Wainwright & Co., Oppenheimer, and Oppenheimer, there's an implied 202.11% upside for Aldeyra Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Oppenheimer
Citigroup
Oppenheimer
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Aldeyra Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/06/2024 | Buy Now | 202.11% | HC Wainwright & Co. | Matthew Caufield | → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/06/2024 | Buy Now | 202.11% | Oppenheimer | Francois Brisebois | $10 → $10 | Reiterates | Outperform → Outperform | Get Alert |
| 04/03/2024 | Buy Now | 202.11% | Oppenheimer | Francois Brisebois | → $10 | Upgrade | Perform → Outperform | Get Alert |
| 04/02/2024 | Buy Now | 202.11% | HC Wainwright & Co. | Matthew Caufield | → $10 | Reinstates | Buy → Buy | Get Alert |
| 10/17/2023 | Buy Now | 141.69% | Citigroup | Yigal Nochomovitz | $25 → $8 | Maintains | Buy | Get Alert |
| 10/17/2023 | Buy Now | — | Oppenheimer | Justin Kim | — | Downgrade | Outperform → Perform | Get Alert |
| 08/09/2023 | Buy Now | 322.96% | Oppenheimer | Justin Kim | → $14 | Reiterates | Outperform → Outperform | Get Alert |
| 06/30/2023 | Buy Now | 353.17% | HC Wainwright & Co. | Matthew Caufield | → $15 | Reiterates | Buy → Buy | Get Alert |
| 06/22/2023 | Buy Now | 353.17% | HC Wainwright & Co. | Matthew Caufield | → $15 | Reiterates | Buy → Buy | Get Alert |
| 06/16/2023 | Buy Now | 353.17% | HC Wainwright & Co. | Matthew Caufield | → $15 | Reiterates | Buy → Buy | Get Alert |
| 06/01/2023 | Buy Now | 655.29% | Citigroup | Yigal Nochomovitz | $28 → $25 | Maintains | Buy | Get Alert |
| 05/05/2023 | Buy Now | 353.17% | HC Wainwright & Co. | Matthew Caufield | → $15 | Reiterates | → Buy | Get Alert |
| 03/10/2023 | Buy Now | 745.92% | Citigroup | Yigal Nochomovitz | $23 → $28 | Maintains | Buy | Get Alert |
| 03/10/2023 | Buy Now | 353.17% | HC Wainwright & Co. | Matthew Caufield | → $15 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | 353.17% | HC Wainwright & Co. | Matthew Caufield | → $15 | Reiterates | → Buy | Get Alert |
| 11/21/2022 | Buy Now | 594.86% | Citigroup | Yigal Nochomovitz | $26 → $23 | Maintains | Buy | Get Alert |
| 06/09/2022 | Buy Now | 685.5% | Citigroup | Yigal Nochomovitz | $21 → $26 | Maintains | Buy | Get Alert |
| 04/27/2022 | Buy Now | 353.17% | HC Wainwright & Co. | Andrew Fein | → $15 | Assumes | → Buy | Get Alert |
| 12/21/2021 | Buy Now | 534.44% | Citigroup | Yigal Nochomovitz | $25 → $21 | Maintains | Buy | Get Alert |
| 12/21/2021 | Buy Now | 353.17% | SVB Leerink | Marc Goodman | $24 → $15 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Aldeyra Therapeutics (ALDX) stock?
The latest price target for Aldeyra Therapeutics (NASDAQ:ALDX) was reported by HC Wainwright & Co. on May 6, 2024. The analyst firm set a price target for $10.00 expecting ALDX to rise to within 12 months (a possible 202.11% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aldeyra Therapeutics (ALDX)?
The latest analyst rating for Aldeyra Therapeutics (NASDAQ:ALDX) was provided by HC Wainwright & Co., and Aldeyra Therapeutics reiterated their buy rating.
When was the last upgrade for Aldeyra Therapeutics (ALDX)?
The last upgrade for Aldeyra Therapeutics Inc happened on April 3, 2024 when Oppenheimer raised their price target to $10. Oppenheimer previously had a perform for Aldeyra Therapeutics Inc.
When was the last downgrade for Aldeyra Therapeutics (ALDX)?
The last downgrade for Aldeyra Therapeutics Inc happened on October 17, 2023 when Oppenheimer changed their price target from N/A to N/A for Aldeyra Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Aldeyra Therapeutics (ALDX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aldeyra Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aldeyra Therapeutics was filed on May 6, 2024 so you should expect the next rating to be made available sometime around May 6, 2025.
Is the Analyst Rating Aldeyra Therapeutics (ALDX) correct?
While ratings are subjective and will change, the latest Aldeyra Therapeutics (ALDX) rating was a reiterated with a price target of $10.00 to $10.00. The current price Aldeyra Therapeutics (ALDX) is trading at is $3.31, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.